Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19145580 | 0.88 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2NPC1RAB9AMTNR1A | |
| SCHEMBL13693420 | 0.87 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL3400792 | 0.87 | HPGD (0.61) | ALDH1A1SMN1; SMN2RAB9AMTNR1AMTNR1B | |
| SCHEMBL3404602 | 0.87 | MTNR1A (0.66) | ALDH1A1SMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL8002914 | 0.85 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2NPC1RAB9AMTNR1A | |
| SCHEMBL24761196 | 0.84 | MTNR1A (0.52) | ALDH1A1SMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL3398650 | 0.84 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2NPC1RAB9ANFKB1 | |
| SCHEMBL7991636 | 0.84 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2NPC1RAB9AMTNR1A | |
| SCHEMBL6552601 | 0.83 | NPC1 (0.63) | SMN1; SMN2NPC1RAB9ALMNAL3MBTL1 | |
| SCHEMBL3401444 | 0.82 | MTNR1A (0.77) | ALDH1A1SMN1; SMN2NPC1RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302847-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250170144-A1 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12161650-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4433062-A1 | THERAPEUTIC COMPOUNDS | Armgo Pharma, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12076327-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-12076326-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-12059426-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4340861-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | Armgo Pharma, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230372358-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230364107-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-2653466-A1 | Agents for treating disorders involving modulation of ryanodine receptors | Les Laboratoires Servier (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2653466-A1 | Agents for treating disorders involving modulation of ryanodine receptors | Les Laboratoires Servier (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2250159-B1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA INC (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2250159-B1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA INC (US) | 2011-12-07 | — | — | EP | disclosed |
| CN-101977902-A | Method for preparing benzothiazepines from gamma-aminoalkylbenzenes | ARMGO PHARMA INC | 2011-02-16 | — | — | CN | disclosed |
| EP-2250159-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | Armgo Pharma, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009111463-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302847-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, MUSK | ALDH1A1 1707/4885SMN1; SMN2 215/4885NPC1 2964/4885 |
| US-12076326-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | RYR1, RYR2, ATP2A1 | ALDH1A1 3285/4885SMN1; SMN2 1289/4885NPC1 1967/4885 |
| US-12076327-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | RYR1, RYR2, ATP2A1 | ALDH1A1 3285/4885SMN1; SMN2 1289/4885NPC1 1967/4885 |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | TPMT, SULT2A1, KCNJ2 | ALDH1A1 57/4885SMN1; SMN2 2828/4885NPC1 2263/4885 |
| US-12059426-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | RYR1, RYR2, MUSK | ALDH1A1 1707/4885SMN1; SMN2 215/4885NPC1 2964/4885 |
| US-12161650-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | RYR1, RYR2, MUSK | ALDH1A1 1707/4885SMN1; SMN2 215/4885NPC1 2964/4885 |
| US-20250170144-A1 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, ATP2A1 | ALDH1A1 3285/4885SMN1; SMN2 1289/4885NPC1 1967/4885 |
| US-20230372358-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, MUSK | ALDH1A1 1707/4885SMN1; SMN2 215/4885NPC1 2964/4885 |
| US-20230364107-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, MUSK | ALDH1A1 1707/4885SMN1; SMN2 215/4885NPC1 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.